Myovant Sciences Ltd.

Myovant Sciences Ltd. (http://myovant.com/) is a United Kingdom-based biopharmaceutical company focused on redefining care for women and for men through purpose-driven science, empowering medicines and transformative advocacy. The Company’s two products include ORGOVYX, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer; and MYFEMBREE, a once-daily oral treatment for the management of heavy menstrual bleeding associated with uterine fibroids. It through its subsidiary, Myovant Sciences GmbH developing supplemental New Drug Application for once-daily MYFEMBREE for the management of moderate to severe pain associated with endometriosis and being assessed for contraceptive efficacy in women ages 18-35 years who are at risk for pregnancy. It is developing Relugolix for the treatment of men with advanced prostate cancer. It is also developing MVT-602, which has completed a Phase IIa study for the treatment of female infertility.

• Myovant Sciences Ltd.